CEO Ron Kurtz was paid $4,650,661 in fiscal year 2025, ↓ down 33.4% from fiscal year 2024, the 11th percentile of its disclosed peer group (SEC filing 0001193125-26-187240 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$4,650,661 ↓ Ron Kurtz total, FY2025 | 11th CEO pay percentile vs peers | 28:1 CEO-to-median pay ratio | 88.4% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
RXST's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ron Kurtz | $630,625 | $0 | $0 | $3,816,530 | $202,935 | $0 | $571 | $4,650,661 |
| Chief Executive Officer, President and Director | ||||||||
| Eric Weinberg | 520,377 | 0 | 0 | 2,218,913 | 108,847 | 0 | 7,000 | 2,855,137 |
| Chief Business Development Officer | ||||||||
| Shelley Thunen | 520,377 | 0 | 0 | 2,218,913 | 108,847 | 0 | 7,000 | 2,855,137 |
| Former Chief Financial Officer | ||||||||
| Ilya Goldshleger | 520,377 | 0 | 0 | 2,218,913 | 108,847 | 0 | 4,783 | 2,852,920 |
| Chief Operating Officer | ||||||||
| Scott Gaines | 401,666 | 0 | 448,683 | 455,540 | 64,628 | 0 | 5,759 | 1,376,276 |
| Chief Customer Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ron Kurtz | $4,650,661 | $6,982,453 | $3,081,597 | ↓ −2,331,792 |
| Eric Weinberg | 2,855,137 | 5,796,727 | 1,652,728 | ↓ −2,941,590 |
| Shelley Thunen | 2,855,137 | 5,796,727 | 1,886,419 | ↓ −2,941,590 |
| Ilya Goldshleger | 2,852,920 | 5,819,227 | 1,885,654 | ↓ −2,966,307 |
| Scott Gaines | 1,376,276 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read RxSight, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper RXST reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the RxSight, Inc. Peer Teardown Report
$4,650,661 Ron Kurtz total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of September 16, 2026 · Source: 0001193125-26-187240 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for RXST
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order RXST
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses RXST in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RXST in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the RxSight, Inc. Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Eric Weinberg | Executive | $2,855,137 |
| Ilya Goldshleger | COO | $2,852,920 |
| Ron Kurtz | CEO | $4,650,661 |
| Scott Gaines | CCO | $1,376,276 |
| Shelley Thunen | CFO | $2,855,137 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| J. Andy Corley | Chair of the Board | $282,489 |
| Julie B. Andrews | Independent Director | $239,989 |
| Juliet Tammenoms Bakker | Independent Director | $234,989 |
| Raymond W. Cohen | Independent Director | $305,622 |
| Robert J. Palmisano | Independent Director | $234,989 |
| Robert Warner | Independent Director | $237,489 |
| Shweta Singh Maniar | Independent Director | $224,989 |
| Tamara R. Fountain, M.D | Independent Director | $229,989 |
| William J. Link, Ph.D | Director | $219,989 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Bakker Juliet Tammenoms | Director | 2026-06-17 | A | 37,037 | — | — | Common | Form 4 ↗ |
| Raymond W. Cohen | Director | 2026-06-17 | A | 30,864 | — | — | Common | Form 4 ↗ |
| J. Andy Corley | Director | 2026-06-17 | A | 37,037 | — | — | Common | Form 4 ↗ |
| Tamara Fountain | Director | 2026-06-17 | A | 37,037 | — | — | Common | Form 4 ↗ |
| Shweta Singh Maniar | Director | 2026-06-17 | A | 37,037 | — | — | Common | Form 4 ↗ |
| Robert J. Palmisano | Director | 2026-06-17 | A | 37,037 | — | — | Common | Form 4 ↗ |
| Robert Warner | Director | 2026-06-17 | A | 37,037 | — | — | Common | Form 4 ↗ |
| Julie B. Andrews | Director | 2026-06-17 | A | 37,037 | — | — | Common | Form 4 ↗ |
| William J. Link Phd | Director | 2026-06-17 | A | 37,037 | — | — | Common | Form 4 ↗ |
| Aziz Mottiwala | Director | 2026-07-24 | A | 2,312,138 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aziz Mottiwala | Director | 2026-07-24 | A | 571,286 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-08-31 | D | 5,370 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-08-31 | A | 5,370 | — | — | Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-08-31 | A | 5,370 | — | — | Common | Form 4 ↗ |
| Mark Wilterding | Chief Financial Officer | 2026-08-31 | D | 20,441 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Wilterding | Chief Financial Officer | 2026-08-31 | A | 20,441 | — | — | Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-08-31 | D | 13,425 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-08-31 | D | 5,370 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-08-31 | A | 13,425 | — | — | Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-02 | D | 2,041 | 7 | 14,205 | Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-02 | D | 2,041 | 7 | 14,205 | Common | Form 4 ↗ |
| Mark Wilterding | Chief Financial Officer | 2026-09-02 | D | 7,765 | 7 | 54,044 | Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-02 | D | 5,100 | 7 | 35,496 | Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | A | 93,984 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | D | 92,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | D | 98,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-05 | A | 161,654 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-05 | D | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | A | 59,483 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | A | 65,742 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | D | 87,437 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | A | 59,483 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-05 | A | 96,129 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-05 | A | 173,913 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-05 | D | 149,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-05 | D | 338,819 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | A | 93,984 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | A | 32,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | A | 82,608 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Wilterding | Chief Financial Officer | 2026-09-05 | A | 258,770 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | A | 73,960 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | D | 120,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | A | 32,258 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ilya Goldshleger | Chief Operating Officer | 2026-09-05 | A | 104,347 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-05 | A | 254,751 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Kurtz | Chief Medical Officer | 2026-09-05 | D | 215,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | D | 92,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-05 | D | 95,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Wilterding | Chief Financial Officer | 2026-09-05 | D | 258,770 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-15 | D | 35,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Weinberg | See remarks | 2026-09-15 | A | 35,168 | 4 | 152,629 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Scott Gaines | RSU | 2025-02-27 | — | — | 13,250 | — | $373,783 |
| Ilya Goldshleger | OPTION | 2025-02-27 | — | — | 125,000 | — | 2,218,913 |
| Scott Gaines | RSU | 2025-05-01 | — | — | 5,000 | — | 74,900 |
| Scott Gaines | OPTION | 2025-02-27 | — | — | 18,285 | — | 324,583 |
| Shelley Thunen | OPTION | 2025-02-27 | — | — | 125,000 | — | 2,218,913 |
| Eric Weinberg | OPTION | 2025-02-27 | — | — | 125,000 | — | 2,218,913 |
| Ron Kurtz | OPTION | 2025-02-27 | — | — | 215,000 | — | 3,816,530 |
| Scott Gaines | OPTION | 2025-07-31 | — | — | 25,000 | — | 130,958 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Scott Gaines | $448,683 | $0 | $455,541 | 0.0% |
| Ilya Goldshleger | 0 | 0 | 2,218,913 | 0.0% |
| Shelley Thunen | 0 | 0 | 2,218,913 | 0.0% |
| Eric Weinberg | 0 | 0 | 2,218,913 | 0.0% |
| Ron Kurtz | 0 | 0 | 3,816,530 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ron Kurtz | Option | 83,813 | 56.07 | — |
| Scott Gaines | RSU | 3,750 | — | 39,075 |
| Scott Gaines | RSU | 7,500 | — | 78,150 |
| Ilya Goldshleger | Option | 51,863 | 56.07 | — |
| Shelley Thunen | Option | 37,500 | 14.95 | — |
| Eric Weinberg | Option | 29,688 | 14.95 | — |
| Eric Weinberg | Option | 51,863 | 56.07 | — |
| Scott Gaines | RSU | 11,593 | — | 120,799 |
| Scott Gaines | Option | 6,250 | 14.95 | — |
| Ilya Goldshleger | Option | 33,334 | 46.24 | — |
| Eric Weinberg | Option | 33,334 | 46.24 | — |
| Scott Gaines | Option | 14,476 | 28.21 | — |
| Ilya Goldshleger | Option | 37,500 | 14.95 | — |
| Ilya Goldshleger | Option | 98,959 | 28.21 | — |
| Shelley Thunen | Option | 33,334 | 46.24 | — |
| Shelley Thunen | Option | 98,959 | 28.21 | — |
| Ron Kurtz | Option | 170,209 | 28.21 | — |
| Shelley Thunen | Option | 51,863 | 56.07 | — |
| Scott Gaines | Option | 22,396 | 7.78 | — |
| Ron Kurtz | Option | 62,500 | 14.95 | — |
| Eric Weinberg | Option | 98,959 | 28.21 | — |
| Scott Gaines | Option | 3,125 | 12.85 | — |
| Scott Gaines | Option | 5,625 | 56.07 | — |
| Scott Gaines | Option | 16,667 | 46.24 | — |
The compensation committee aims to provide competitive compensation to attract and retain top talent, create a direct link between business plan achievement and employee compensation, motivate the focus on annual and long-term performance goals, and align employee and investor interests through long-term incentives while managing share usage and equity dilution.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-16 | 21,236,615 | 2,742,189 | 43,385 | 88.4% | Passed |
| 2025 | 2025-06-03 | 22,365,356 | 3,322,193 | 98,678 | 86.73% | Passed |
| 2024 | 2024-06-06 | 22,608,292 | 1,123,950 | 395,359 | 95.26% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-16 | 88.4%a |
| 2025 | 2025-06-03 | 86.73%b |
| 2024 | 2024-06-06 | 95.26%c |
a. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote AGAINST this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote AGAINST this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 28 : 1 |
|---|---|
| CEO total compensation | $4,650,661 |
| Median employee compensation | $164,848 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Raymond W. CohenIndependent · Audit · Compensation · Partial-year service | $28,125 | $277,497 | $0 | — | $0 | $305,622 |
| J. Andy CorleyIndependent · Board Chair · Compensation · Governance | 112,500 | 169,989 | 0 | — | 0 | 282,489 |
| Julie B. AndrewsIndependent · Audit (Chair) | 70,000 | 169,989 | 0 | — | 0 | 239,989 |
| Robert WarnerIndependent · Compensation · Governance (Chair) | 67,500 | 169,989 | 0 | — | 0 | 237,489 |
| Juliet Tammenoms BakkerIndependent · Audit · Governance | 65,000 | 169,989 | 0 | — | 0 | 234,989 |
| Robert J. PalmisanoIndependent · Compensation (Chair) | 65,000 | 169,989 | 0 | — | 0 | 234,989 |
| Tamara R. Fountain, M.DIndependent · Audit | 60,000 | 169,989 | 0 | — | 0 | 229,989 |
| Shweta Singh ManiarIndependent · Governance | 55,000 | 169,989 | 0 | — | 0 | 224,989 |
| William J. Link, Ph.DNot independent | 50,000 | 169,989 | 0 | — | 0 | 219,989 |
| Ron Kurtz, M.DEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $170,000 |
| Per board meeting fee | $1,500 |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | $3 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $573,125 |
| Equity awards (grant-date value) | $1,637,409 |
| All other compensation | $0 |
| Total cost of the board | $2,210,534 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies RxSight, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including RxSight, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Aon, plc | 2025 | Gregory Case | $1,500,000 | $68,769,941 | $0 | $2,437,500 | $73,742,639 |
| 2 | PROCEPT BioRobotics Corporation | 2025 | Larry Wood | 304,830 | 7,217,251 | 7,226,599 | 243,864 | 16,783,853 |
| 3 | Twist Bioscience Corporation | 2025 | Emily Leproust | 720,000 | 11,998,134 | 0 | 932,918 | 13,781,570 |
| 4 | Silk Road Medical, Inc. | 2023 | Chas McKhann | 105,871 | 13,123,059 | 0 | 93,275 | 13,423,834 |
| 5 | Glaukos Corporation | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 6 | Vericel Corporation | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 7 | iRhythm Technologies, Inc. | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 8 | TransMedics Group, Inc. | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 9 | Alphatec Holdings, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 10 | ADMA Biologics, Inc. | 2025 | Adam Grossman | 925,000 | 4,049,994 | 4,049,998 | 1,156,250 | 10,237,326 |
| 11 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 12 | Inspire Medical Systems, Inc. | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 13 | STAAR Surgical Company | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 14 | SI-BONE, Inc. | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 15 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 16 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 17 | Inari Medical, Inc. | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| 18 | RxSight, Inc. | 2025 | Ron Kurtz | 630,625 | 0 | 3,816,530 | 202,935 | 4,650,661 |
| 19 | LeMaitre Vascular, Inc. | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 20 | OrthoPediatrics Corp. | 2025 | David Bailey | 550,000 | 2,445,200 | 0 | 322,281 | 3,331,481 |
| — | Axonics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| RxSight, Inc. | 32.18% | Option 100 | not disclosed | Aon |
| ADMA Biologics, Inc. | 125% | RSU 50 · Options 50 | not disclosed | Pay Governance LLC |
| Alphatec Holdings, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| Aon, plc | 100% | PSU 100 | No | Meridian Compensation Partners, LLC |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure, Inc. | 141% | PSU 70 · RSU 30 | No | Korn Ferry |
| Axonics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Glaukos Corporation | 177.5% | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Inari Medical, Inc. | 118% | RSU 75 · Option 25 | not disclosed | FW Cook |
| Inspire Medical Systems, Inc. | 111.4% | PSU 50 · RSU 50 | No | Aon |
| iRhythm Technologies, Inc. | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| LeMaitre Vascular, Inc. | not disclosed | Option 50 · RSU 25 · PSU 25 | No | not disclosed |
| OrthoPediatrics Corp. | 78.2% | RSU 100 | not disclosed | NFP Compensation Consulting |
| PROCEPT BioRobotics Corporation | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| SI-BONE, Inc. | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| Silk Road Medical, Inc. | not disclosed | PSU 50 · RSU 50 | Yes — Total Stockholder Return (TSR) relative to peer group | Compensia, Inc. |
| STAAR Surgical Company | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| TransMedics Group, Inc. | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Twist Bioscience Corporation | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Ron Kurtz | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Summary Compensation Table” · page 41. As printed: 4,650,661. Filing ↗ |
| 2 | Section 01, Eric Weinberg | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Summary Compensation Table” · page 41. As printed: 2,855,137. Filing ↗ |
| 3 | Section 01, Shelley Thunen | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Summary Compensation Table” · page 41. As printed: 2,855,137. Filing ↗ |
| 4 | Section 01, Ilya Goldshleger | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Summary Compensation Table” · page 41. As printed: 2,852,920. Filing ↗ |
| 5 | Section 01, Scott Gaines | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Summary Compensation Table” · page 41. As printed: 1,376,276. Filing ↗ |
| 6 | Section 03, Scott Gaines RSU | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 1250591–1250599 |
| 7 | Section 03, Ilya Goldshleger OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r7 · c3 · span 886066–886073 |
| 8 | Section 03, Scott Gaines RSU | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 1256073–1256080 |
| 9 | Section 03, Scott Gaines OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗ |
| 10 | Section 03, Shelley Thunen OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r5 · c3 · span 879624–879631 |
| 11 | Section 03, Eric Weinberg OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r6 · c3 · span 882840–882847 |
| 12 | Section 03, Ron Kurtz OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t19 · r4 · c3 · span 876407–876414 |
| 13 | Section 03, Scott Gaines OPTION | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 1261582–1261590 |
| 14 | Section 07, pay ratio | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “CEO Pay Ratio”. As printed: 28 : 1. Filing ↗ |
| 15 | Section 08, Raymond W. Cohen | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 305,622. Filing ↗machine: span 503910–504119 |
| 16 | Section 08, J. Andy Corley | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 282,489. Filing ↗machine: span 471679–471888 |
| 17 | Section 08, Julie B. Andrews | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 239,989. Filing ↗machine: span 475712–475921 |
| 18 | Section 08, Robert Warner | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 237,489. Filing ↗machine: span 487798–488007 |
| 19 | Section 08, Juliet Tammenoms Bakker | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 234,989. Filing ↗machine: span 479752–479961 |
| 20 | Section 08, Robert J. Palmisano | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 234,989. Filing ↗machine: span 483778–483987 |
| 21 | Section 08, Tamara R. Fountain, M.D | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 229,989. Filing ↗machine: span 499886–500095 |
| 22 | Section 08, Shweta Singh Maniar | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 224,989. Filing ↗machine: span 495854–496063 |
| 23 | Section 08, William J. Link, Ph.D | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 219,989. Filing ↗machine: span 491827–492036 |
| 24 | Section 08, Ron Kurtz, M.D | DEF 14A | 2026-04-28 | 0001193125-26-187240 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 02, Bakker Juliet Tammenoms 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275823 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Raymond W. Cohen 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, J. Andy Corley 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Tamara Fountain 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275843 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Shweta Singh Maniar 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275848 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Robert J. Palmisano 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275851 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Robert Warner 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275856 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Julie B. Andrews 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275819 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, William J. Link Phd 2026-06-17 | Form 4 | 2026-06-18 | 0001193125-26-275841 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Aziz Mottiwala 2026-07-24 | Form 4 | 2026-07-24 | 0001193125-26-316544 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Aziz Mottiwala 2026-07-24 | Form 4 | 2026-07-24 | 0001193125-26-316544 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Eric Weinberg 2026-08-31 | Form 4 | 2026-09-02 | 0001193125-26-380710 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Eric Weinberg 2026-08-31 | Form 4 | 2026-09-02 | 0001193125-26-380710 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Ilya Goldshleger 2026-08-31 | Form 4 | 2026-09-02 | 0001193125-26-380711 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Mark Wilterding 2026-08-31 | Form 4 | 2026-09-02 | 0001193125-26-380713 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Mark Wilterding 2026-08-31 | Form 4 | 2026-09-02 | 0001193125-26-380713 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Ron Kurtz 2026-08-31 | Form 4 | 2026-09-02 | 0001193125-26-380714 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Ilya Goldshleger 2026-08-31 | Form 4 | 2026-09-02 | 0001193125-26-380711 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Ron Kurtz 2026-08-31 | Form 4 | 2026-09-02 | 0001193125-26-380714 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Eric Weinberg 2026-09-02 | Form 4 | 2026-09-02 | 0001193125-26-380710 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Ilya Goldshleger 2026-09-02 | Form 4 | 2026-09-02 | 0001193125-26-380711 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Mark Wilterding 2026-09-02 | Form 4 | 2026-09-02 | 0001193125-26-380713 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Ron Kurtz 2026-09-02 | Form 4 | 2026-09-02 | 0001193125-26-380714 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Ron Kurtz 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Ron Kurtz 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Ron Kurtz 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Ron Kurtz 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Ron Kurtz 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Ron Kurtz 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Mark Wilterding 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386841 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Ilya Goldshleger 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Ron Kurtz 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Ron Kurtz 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386838 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Eric Weinberg 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386840 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Mark Wilterding 2026-09-05 | Form 4 | 2026-09-09 | 0001193125-26-386841 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Eric Weinberg 2026-09-15 | Form 4 | 2026-09-16 | 0001295814-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Eric Weinberg 2026-09-15 | Form 4 | 2026-09-16 | 0001295814-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 06, 2026 vote | Form 8-K | 2026-06-16 | 0001193125-26-272688 | Item 5.07 · say-on-pay result. As reported: 88.4% (votes for as printed: 21,236,615). Filing ↗ |
| 81 | Section 06, 2025 vote | Form 8-K | 2025-06-04 | 0000950170-25-081636 | Item 5.07 · say-on-pay result. As reported: 86.73% (votes for as printed: 22,365,356). Filing ↗ |
| 82 | Section 06, 2024 vote | Form 8-K | 2024-06-06 | 0000950170-24-069895 | Item 5.07 · say-on-pay result. As reported: 95.26% (votes for as printed: 22,608,292). Filing ↗ |
| 83 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 84 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 85 | Section 09b board cost (computed) | Computed | — | — | Cash 573,125 + equity 1,637,409 + all other 0 = 2,210,534, summed across the director compensation table rows.machine: formula: Σ = 2,210,534 |
| 86 | Aon, plc, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187428 | CEO total compensation as printed in Aon, plc's own proxy. As printed: 73,742,639. Filing ↗machine: t52 · r4 · c17 · span 1294068–1294078 |
| 87 | PROCEPT BioRobotics Corporation, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001588978-26-000017 | CEO total compensation as printed in PROCEPT BioRobotics Corporation's own proxy. As printed: 16,783,853. Filing ↗machine: r2 · c48 · span 520911–520921 |
| 88 | Twist Bioscience Corporation, Section 10b CEO total | DEF 14A | 2026-01-06 | 0001581280-26-000006 | CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. Filing ↗machine: t34 · r2 · c15 · span 1510951–1510961 |
| 89 | Silk Road Medical, Inc., Section 10b CEO total | DEF 14A | 2024-04-26 | 0001397702-24-000024 | CEO total compensation as printed in Silk Road Medical, Inc.'s own proxy. As printed: 13,423,834. Filing ↗machine: r2 · c8 · span 1756696–1756706 |
| 90 | Glaukos Corporation, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-157829 | CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952 |
| 91 | Vericel Corporation, Section 10b CEO total | DEF 14A | 2026-03-19 | 0001308179-26-000094 | CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754 |
| 92 | iRhythm Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001388658-26-000030 | CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508 |
| 93 | TransMedics Group, Inc., Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-150357 | CEO total compensation as printed in TransMedics Group, Inc.'s own proxy. As printed: 10,915,533. Filing ↗machine: r3 · c39 · span 572169–572179 |
| 94 | Alphatec Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191867 | CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158 |
| 95 | ADMA Biologics, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001140361-26-014799 | CEO total compensation as printed in ADMA Biologics, Inc.'s own proxy. As printed: 10,237,326. Filing ↗machine: r2 · c25 · span 619658–619669 |
| 96 | AtriCure, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001323885-26-000010 | CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373 |
| 97 | Inspire Medical Systems, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001140361-26-010490 | CEO total compensation as printed in Inspire Medical Systems, Inc.'s own proxy. As printed: 7,711,784. Filing ↗machine: r2 · c25 · span 1164868–1164877 |
| 98 | STAAR Surgical Company, Section 10b CEO total | DEF 14A | 2026-05-04 | 0000718937-26-000015 | CEO total compensation as printed in STAAR Surgical Company's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486 |
| 99 | SI-BONE, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001459839-26-000049 | CEO total compensation as printed in SI-BONE, Inc.'s own proxy. As printed: 7,453,235. Filing ↗machine: r3 · c18 · span 626969–626978 |
| 100 | Veracyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 101 | Artivion, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001999371-26-007510 | CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882 |
| 102 | Inari Medical, Inc., Section 10b CEO total | DEF 14A | 2024-03-13 | 0001193125-24-066805 | CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517 |
| 103 | RxSight, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187240 | CEO total compensation as printed in RxSight, Inc.'s own proxy. As printed: 4,650,661. Filing ↗ |
| 104 | LeMaitre Vascular, Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0001193125-26-153877 | CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. Filing ↗machine: r3 · c18 · span 564038–564047 |
| 105 | OrthoPediatrics Corp., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001425450-26-000027 | CEO total compensation as printed in OrthoPediatrics Corp.'s own proxy. As printed: 3,331,481. Filing ↗machine: r2 · c36 · span 363407–363416 |
| 106 | Section 10a, Aon, plc reciprocity | DEF 14A | — | 0001193125-26-187428 | Aon, plc's most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 107 | Section 10a, Veracyte, Inc. reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 108 | Section 10a, PROCEPT BioRobotics Corporation reciprocity | DEF 14A | — | 0001588978-26-000017 | PROCEPT BioRobotics Corporation names RxSight, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 109 | Section 10a, AtriCure, Inc. reciprocity | DEF 14A | — | 0001323885-26-000010 | AtriCure, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 110 | Section 10a, Silk Road Medical, Inc. reciprocity | DEF 14A | — | 0001397702-24-000024 | Silk Road Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 111 | Section 10a, iRhythm Technologies, Inc. reciprocity | DEF 14A | — | 0001388658-26-000030 | iRhythm Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 112 | Section 10a, Vericel Corporation reciprocity | DEF 14A | — | 0001308179-26-000094 | Vericel Corporation names RxSight, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 113 | Section 10a, SI-BONE, Inc. reciprocity | DEF 14A | — | 0001459839-26-000049 | SI-BONE, Inc. names RxSight, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 114 | Section 10a, ADMA Biologics, Inc. reciprocity | DEF 14A | — | 0001140361-26-014799 | ADMA Biologics, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 115 | Section 10a, TransMedics Group, Inc. reciprocity | DEF 14A | — | 0001193125-26-150357 | TransMedics Group, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 116 | Section 10a, Glaukos Corporation reciprocity | DEF 14A | — | 0001193125-26-157829 | Glaukos Corporation's most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 117 | Section 10a, LeMaitre Vascular, Inc. reciprocity | DEF 14A | — | 0001437749-23-010217 | LeMaitre Vascular, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 118 | Section 10a, Inari Medical, Inc. reciprocity | DEF 14A | — | 0001193125-24-066805 | Inari Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 119 | Section 10a, Artivion, Inc. reciprocity | DEF 14A | — | 0001999371-26-007510 | Artivion, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 120 | Section 10a, Alphatec Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-191867 | Alphatec Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 121 | Section 10a, Inspire Medical Systems, Inc. reciprocity | DEF 14A | — | 0001140361-26-010490 | Inspire Medical Systems, Inc.'s most recent proxy was read; its disclosed peer group does not include RxSight, Inc.. Filing ↗ |
| 122 | Section 10a, STAAR Surgical Company reciprocity | DEF 14A | — | 0000718937-26-000015 | STAAR Surgical Company names RxSight, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the RxSight, Inc. Executive Compensation Report
$1,500